Zobrazeno 1 - 10
of 21 353
pro vyhledávání: '"Rifampicin"'
Publikováno v:
Journal of Marine Medical Society, Vol 26, Iss 3, Pp 382-385 (2024)
Background: Tuberculosis (TB) continues to be a major cause of morbidity and mortality worldwide. The main strategy to fight the pandemic is the development of rapid, accurate diagnostic tests, which helps to reduce the time for initiation of therapy
Externí odkaz:
https://doaj.org/article/ca8de7b125e44be4ba5f8da59b06ce3c
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 13, Iss 1, Pp 1-12 (2024)
Abstract Background Multidrug- or rifampicin-resistant tuberculosis (TB; MDR/RR-TB) is a significant public health threat. However, the mechanisms involved in its transmission in Sichuan, China are unclear. To provide a scientific basis for MDR/RR-TB
Externí odkaz:
https://doaj.org/article/c09415a66bf84dec95af5b47aed7bfc6
Autor:
Yishak Abraham, Dawit Getachew Assefa, Tesfahunegn Hailemariam, Desye Gebrie, Dejene Tolossa Debela, Simon Tsegaye Geleta, Dagmawit Tesfaye, Michele Joseph, Tsegahun Manyazewal
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-22 (2024)
Abstract Background Drug-resistant tuberculosis (DR-TB) remains a threat to public health. Shorter regimens have been proposed as potentially valuable treatments for multidrug or rifampicin resistant tuberculosis (MDR/RR-TB). We undertook a systemati
Externí odkaz:
https://doaj.org/article/dfb34cffff99493b8d5a0a02c00b116d
Autor:
Pankaj Jorwal, Binit Kumar Singh, Ankita Anand, Faisal Khan, Krisha Khandelwal, Payal Sharma, Neeraj Nischal, Manish Soneja, Prayas Sethi, Shikha Dhawan, Naveet Wig
Publikováno v:
International Journal of Mycobacteriology, Vol 13, Iss 3, Pp 275-281 (2024)
Background: Tuberculosis (TB) is caused due to the infection of Mycobacterium tuberculosis (MTB) and it can infect the various parts of the human body. The disease is highly prevalent and is the second most common cause of death worldwide after COVID
Externí odkaz:
https://doaj.org/article/090d8ac1dc75438f847651ee44d5f3ae
Autor:
Zakayo Maingi Mwangi, Samson Ireri, Haron Opwaka, Leon Otieno, Joan Simam, Frank Gekara Onyambu, Nellie Mukiri
Publikováno v:
International Journal of Mycobacteriology, Vol 13, Iss 3, Pp 258-264 (2024)
Background: Drug-resistant tuberculosis (DR-TB) poses a major global challenge to public health and therapeutics. It is an emerging global concern associated with increased morbidity and mortality mostly seen in the low- and middle-income countries.
Externí odkaz:
https://doaj.org/article/f570af25d1f1422db1138d73598bf109
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Rifampicin-resistant pulmonary tuberculosis (RR-PTB) presents a significant threat to global public health security. China bears a substantial burden of RR-PTB cases globally, with Guizhou Province experiencing particularly alarmi
Externí odkaz:
https://doaj.org/article/2f35a7fb2b8d49629eabbaf0edd0d55c
Publikováno v:
Infection and Drug Resistance, Vol Volume 17, Pp 4223-4236 (2024)
Song Song,1,* Honghong Xu,1,* Jiawei Cao,2,* Guanghong Wu,2 Haiyan Sun,1 Xiaoqi Dai,1 Xuekui Li,1 Meng Chen,1 Menghan Zhang,1 Yueming Yan,1 Jingfeng Tong,3 Zhongdong Wang1 1Institute of Tuberculosis Control, Qingdao Preventive Medicine Re
Externí odkaz:
https://doaj.org/article/f2775110358f45b3a7d92150f57855e4
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 38, Iss , Pp 292-301 (2024)
Background: Tuberculosis (TB), one of the deadliest infectious diseases globally, is increasingly exacerbated in China by the emergence of resistant Mycobacterium tuberculosis (MTB) strains. Drug-resistant TB, including mono-drug-resistant TB, multid
Externí odkaz:
https://doaj.org/article/e50bbc5a6fce4f29b69b22683504f482
Autor:
Pooja Shah, Sae Pol, Esther Prabhakaran, Bhakti Karmalkar, Vaishali Gaikwad, Sujata Dharamshale, Rajesh Karyakarte
Publikováno v:
Perspectives In Medical Research, Vol 12, Iss 02, Pp 47-51 (2024)
Background: Tuberculosis (TB) remains a significant public health challenge in developing countries, including India, where children under 15 years account for 12% of all TB cases. The National Tuberculosis Elimination Programme (NTEP) recommends the
Externí odkaz:
https://doaj.org/article/fceddc17e8104c838b786f496727d2f1
Autor:
Vijayalakshmi Jawaharlal Nehru, Maria Jose Vandakunnel, Usharani Brammacharry, Venkateswari Ramachandra, Gunavathy Pradhabane, Balasundaram Revathi Mani, Azger Dusthackeer VN, Muthuraj Muthaiah
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Fluoroquinolone resistance is a major challenge in treating Multidrug-Resistant Tuberculosis globally. The GenoType MTBDRsl Ver 2.0, endorsed by the WHO, was used to characterize fluoroquinolone resistance. The fluoroquinolone resistance rat
Externí odkaz:
https://doaj.org/article/279d15a4fa174c7bb54b336ed699a248